120O Pembrolizumab (Pembro) with or without lenvatinib (Lenva) in first-line metastatic NSCLC with PD-L1 TPS ≥1% (LEAP-007): A phase III, randomized, double-blind study.

Authors :: Yang, J.C-H.
Luft, A.
De La Mora Jiménez, E.
Lee, J.S.
Koralewski, P.
Karadurmus, N.
Sugawara, S.
Livi, L.
Basappa, N.S.
Quantin, X.
Dudnik, J.
Moran Ortiz, D.
Mekhail, T.
Okpara, C.E.
Zimmer, Z.
Samkari, A.
Bhagwati, N.
Csőszi, T.
Source :: Annals of Oncology. 2021 Supplement 7, Vol. 32, pS1429-S1430. 2p.
Publication Year :: 2021

Subjects :: *PROGRAMMED death-ligand 1
*NON-small-cell lung carcinoma
*PEMBROLIZUMAB
*METASTASIS

Full Text Access

Tools